Table 2. Best-Corrected Visual Acuity Letter Score and Change in BCVA From Baseline to Month 12 for the Full Analysis Set.
| Parameter/Visita | Ranibizumab (n=141) | Aflibercept (n=137) |
|---|---|---|
| Baseline | ||
| BCVA letter score (logMAR) [approximate Snellen equivalent] | ||
| No. | 141 | 137 |
| Mean (SD) | 65.3 (15.10) [20/50] | 65.1 (12.53) [20/50] |
| Median (range) | 68.0 (23 to 90) [20/40] | 67.0 (23 to 89) [20/50] |
| Stratification by BCVA letter score [approximate Snellen equivalent], No. (%) | ||
| <39 [<20/160] | 8 ( 5.7) | 6 ( 4.4) |
| 39-54 [20/160 to <20/80] | 27 ( 19.1) | 19 ( 13.9) |
| 55-69 [20/80 to <20/40] | 38 ( 27.0) | 53 ( 38.7) |
| 70-84 [20/40 to <20/20] | 58 ( 41.1) | 56 ( 40.9) |
| 85-100 [≥20/20] | 10 ( 7.1) | 3 ( 2.2) |
| Week 4 | ||
| BCVA letter score (logMAR) [approximate Snellen equivalent] | ||
| No. | 138 | 137 |
| Mean (SD) | 67.8 (13.53) [20/40] | 65.3 (13.19) [20/50] |
| Median (range) | 71.0 (34 to 94) [20/40] | 68.0 (22 to 88) [20/40] |
| Stratification by BCVA letter score [approximate Snellen equivalent], No. (%) | ||
| <39 [<20/160] | 5 ( 3.6) | 6 ( 4.4) |
| 39-54 [20/160 to <20/80] | 20 ( 14.5) | 25 ( 18.2) |
| 55-69 [20/80 to <20/40] | 40 ( 29.0) | 47 ( 34.3) |
| 70-84 [20/40 to <20/20] | 66 ( 47.8) | 54 ( 39.4) |
| 85-100 [≥20/20] | 7 ( 5.1) | 5 ( 3.6) |
| Change in BCVA letter score from baselineb | ||
| No. | 138 | 137 |
| Mean (SD) | 2.5 (8.47) | 0.2 (8.55) |
| Median (range) | 1.0 (−19 to 39) | 0.0 (−31 to 21) |
| Stratification by change in BCVA letter score, No. (%) | ||
| Gained ≥15 letters | 11 ( 8.0) | 5 ( 3.6) |
| Gained 10-14 letters | 11 ( 8.0) | 10 ( 7.3) |
| Gained 1-9 letters | 56 ( 40.6) | 52 ( 38.0) |
| Lost 0-9 letters | 53 ( 38.4) | 60 ( 43.8) |
| Lost 10-14 letters | 5 ( 3.6) | 3 ( 2.2) |
| Lost ≥15 letters | 2 ( 1.4) | 7 ( 5.1) |
| Week 8 | ||
| BCVA letter score (logMAR) [approximate Snellen equivalent] | ||
| No. | 137 | 137 |
| Mean (SD) | 70.4 (15.31) [20/40] | 68.7 (13.46) [20/40] |
| Median (range) | 76.0 (27 to 94) [20/32] | 72.0 (11 to 90) [20/40] |
| Stratification by BCVA letter score [approximate Snellen equivalent], No. (%) | ||
| <39 [<20/160] | 5 ( 3.6) | 4 ( 2.9) |
| 39-54 [20/160 to <20/80] | 19 ( 13.9) | 15 ( 10.9) |
| 55-69 [20/80 to <20/40] | 29 ( 21.2) | 41 ( 29.9) |
| 70-84 [20/40 to <20/20] | 64 ( 46.7) | 68 ( 49.6) |
| 85-100 [≥20/20] | 20 ( 14.6) | 9 ( 6.6) |
| Change in BCVA letter score from baselineb | ||
| No. | 137 | 137 |
| Mean (SD) | 5.3 (9.07) | 3.6 (10.86) |
| Median (Range) | 4.0 (−15 to 49) | 3.0 (−33 to 42) |
| Stratification by change in BCVA letter score, No. (%) | ||
| Gained ≥15 letters | 18 ( 13.1) | 18 ( 13.1) |
| Gained 10-14 letters | 18 ( 13.1) | 21 ( 15.3) |
| Gained 1-9 letters | 69 ( 50.4) | 48 ( 35.0) |
| Lost 0-9 letters | 27 ( 19.7) | 40 ( 29.2) |
| Lost 10-14 letters | 4 ( 2.9) | 2 ( 1.5) |
| Lost ≥15 letters | 1 ( 0.7) | 8 ( 5.8) |
| Month 12 | ||
| BCVA letter score (logMAR) [approximate Snellen equivalent], No. (%) | ||
| No. | 127 | 121 |
| Mean (SD) | 72.9 (15.54) [20/32] | 70.5 (14.63) [20/40] |
| Median (range) | 78.0 (5 to 95) [20/25] | 74.0 (36 to 91) [20/32] |
| Stratification by BCVA letter score [approximate Snellen equivalent], No. (%) | ||
| <39 [<20/160] | 4 ( 3.1) | 5 ( 4.1) |
| 39-54 [20/160 to <20/80] | 13 ( 10.2) | 13 ( 10.7) |
| 55-69 [20/80 to <20/40] | 22 ( 17.3) | 25 ( 20.7) |
| 70-84 [20/40 to <20/20] | 63 ( 49.6) | 58 ( 47.9) |
| 85-100 [≥20/20] | 25 ( 19.7) | 20 ( 16.5) |
| Change in BCVA letter score from baselineb | ||
| No. | 127 | 121 |
| Mean (SD) | 6.9 (12.25) | 5.2 (12.83) |
| Median (range) | 6.0 (−41 to 52) | 5.0 (−38 to 37) |
| Stratification by change in BCVA letter score, No. (%) | ||
| Gained ≥15 letters | 28 ( 22.0) | 25 ( 20.7) |
| Gained 10-14 letters | 17 ( 13.4) | 20 ( 16.5) |
| Gained 1-9 letters | 52 ( 40.9) | 34 ( 28.1) |
| Lost 0-9 letters | 24 ( 18.9) | 28 ( 23.1) |
| Lost 10-14 letters | 2 ( 1.6) | 8 ( 6.6) |
| Lost ≥15 letters | 4 ( 3.1) | 6 ( 5.0) |
Abbreviation: BCVA, best-corrected visual acuity.
a
Mandatory visit times are included for the analysis: baseline, week 4, week 8, and month 12.
b
The last available nonmissing value collected before the start of treatment in the study eye. One participant in the aflibercept arm had baseline BCVA assessed using a Snellen chart instead of a logMAR chart. The BCVA total score for that participant was converted from Snellen to logMAR.